Advertisement

Erratum

        Referencing errors have been detected in the article “Ventral Striatum Binding of a Dopamine D2/3 Receptor Agonist But Not Antagonist Predicts Normal Body Mass Index” by Caravaggio et al. (2015; 77:196–202). Detailed corrections are as follows:
        Page 199, column 1, 1st paragraph: “Although D3R function has been suggested to affect susceptibility for obesity in rodents (30), evidence has been mixed (32).”
        Reference 30 is incorrect. The correct reference, which does not appear in the published reference list, is: McQuade JA, Benoit SC, Xu M, Woods SC, Seeley RJ (2004): High-fat diet induced adiposity in mice with targeted disruption of the dopamine-3 receptor gene. Behav Brain Res. 151:313-9.
        Reference 32 is incorrect. The correct reference, which does not appear in the published reference list, is: Thanos PK, Michaelides M, Ho CW, Wang GJ, Newman AH, Heidbreder CA, et al. (2008): The effects of two highly selective dopamine D3 receptor antagonists (SB-277011A and NGB-2904) on food self-administration in a rodent model of obesity. Pharmacol Biochem Behav. 89:499-507.
        Page 199, column 2, 1st paragraph: “With the use of an amphetamine challenge in healthy subjects, it has been estimated that [11C]-(+)-PHNO is 1.65 times more sensitive to changes in endogenous dopamine in the VS compared with [11C]-raclopride (36).”
        Reference 36 is incorrect and should instead be reference 34.
        Page 199, column 2, 1st paragraph: “Given that D3Rs have a > 20-fold higher affinity for dopamine than D2Rs in vitro (15,16), any reductions in endogenous dopamine levels would affect [11C]-(+)-PHNO BPND at D2Rs before D3Rs (36).”
        References 15 and 16 are incorrect. The correct references, which do not appear in the published reference list, are: 1) Freedman SB, Patel S, Marwood R, Emms F, Seabrook GR, Knowles MR, McAllister G (1994): Expression and pharmacological characterization of the human D3 dopamine receptor. J Pharmacol Exp Ther. 268:417-26; and 2) Sokoloff P, Andrieux M, Besançon R, Pilon C, Martres MP, Giros B, Schwartz JC (1992): Pharmacology of human dopamine D3 receptor expressed in a mammalian cell line: comparison with D2 receptor. Eur J Pharmacol. 225:331-7.
        Page 200, column 2, 1st paragraph: “However, our interpretation is consistent with recent findings of a nonlinear relationship between sensitivity to reward (SR) and BMI (31), which has been replicated in children (33).”
        Reference 31 is incorrect and should instead be reference 30. Reference 33 is incorrect and should instead be reference 32.

        Linked Article

        • Ventral Striatum Binding of a Dopamine D2/3 Receptor Agonist But Not Antagonist Predicts Normal Body Mass Index
          Biological PsychiatryVol. 77Issue 2
          • Preview
            Positron emission tomography research has shown that dopamine D2/3 receptor (D2/3R) availability is negatively correlated with body mass index (BMI) in obese but not in healthy subjects. However, previous positron emission tomography studies have not looked specifically at the ventral striatum (VS), which plays an important role in motivation and feeding. Furthermore, these studies have only used antagonist radiotracers. Normal-weight rats given free access to high-fat diets demonstrate behavioral sensitization to D2/3R agonists but not to antagonists.
          • Full-Text
          • PDF